ArticleClinical and translational science2026
Impact of CYP2D6 Metabolizer Status on Ondansetron Efficacy in Early Pregnancy Induced Nausea and Vomiting: A Case Control Study.
Article in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Real-world data investigating CYP2D6 on the efficacy of ondansetron for nausea and vomiting in pregnancy (NVP) is lacking. Evidence shows CYP2D6 ultrarapid metabolizers are at risk of ondansetron nonresponse due to increased metabolism. We conducted a retrospective cohort study of early pregnant patients on ondansetron for NVP. Genotype data for 11 CYP2D6 variants and copy number variations were translated into activity score (AS) and metabolizer status: poor (PM), intermediate (IM), normal (NM), and ultrarapid (UM) metabolizers. A total of 264 women met inclusion/exclusion criteria (99 cases and 165 controls). Multivariate regression analyses of metabolizer status and AS were adjusted for significant independent variables. The majority had gravidity of two, singleton pregnancy, a median age of 28 (interquartile range [IQR] 24-31) years, and identified as White (65.5%). Ondansetron dose was similar among the cohort and half received other antiemetics simultaneously. Clinical characteristics between cases and controls did not differ except for gestational age (8 vs. 10 weeks, p = 0.004) and primigravida rate (45.5% vs. 32.7%, p = 0.017). When adjusted for covariates, metabolizer status was not associated with response. UM/NM had non-significantly higher risk of nonresponse (odds ratio [OR] 1.53, 95% confidence interval [CI], 0.88-2.66) compared to PM/IM. Similar trends were observed with higher CYP2D6 AS showing increased risk of nonresponse (OR 1.22, 95% CI [0.81-1.85]). This study found no significant differences in ondansetron response in early pregnancy based on CYP2D6 UM/NM versus PM/IM and AS. Additional prospective investigations are necessary to confirm the CYP2D6 effect on ondansetron efficacy in pregnant patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.